Abstract:Abstract BACKGROUND Despite making up roughly one quarter of the patients with inflammatory bowel diseases (IBD) in the United States, older adults are an understudied population. Chronic steroid use may be as high as 40% in this population and advanced therapies are often deferred, even though long-term treatment goals are to achieve endoscopic remission utilizing steroid-sparing agents. In order to further explore this, we assessed differences in medication usage between older and younger adults with IBD, stratified by disease activity. METHODS We analyzed surveys from the Crohn’s and Colitis Foundation’s IBD Qorus learning health system for patient visits between 6/1/22 and 10/31/22. Patients were stratified by age (>60 years vs. ≤ 60 years), whether mucosal healing was achieved, and patients’ symptoms (mild or moderate-severe) based on PRO-2 UC and PRO-3 CD scores. Univariable analyses were conducted using Chi-square analysis or Fisher’s exact test where appropriate. RESULTS Overall there were 3,470 patient visits across 35 sites. 31% of the patients were >60 years old, 46.9% were male and 58.6% had Crohn’s disease (Table 1). In our cohort, 51.2% of older adults were treated with advanced therapies, 72.4% were in clinical remission (vs. 62.6% in younger adults, p<0.01), and 51.3% achieved mucosal healing (vs. 46.7% of younger adults, p<0.01). Only 5.7% of older patients had been treated with systemic steroids in the preceding 3 months. Older patients were more likely to be treated with mesalamine (18.9% vs. 12.6%, p<.001) and anti-integrins (15.2% vs. 12.5%, p=.02) but less likely to be treated with anti-IL-12/23 inhibitors (12.6% vs. 15.5%, p=.01). Amongst all patients with active disease, there was no difference in advanced therapy usage regardless of the whether the disease activity was mild or moderate-severe (Table 2). Among older adults not achieving mucosal healing, providers were less likely to optimize current therapy (13.3% vs. 17.3% younger adults, p=.008) or add a new therapy (10% vs. 13% younger adults, p=.02), citing that in 21% of cases they believed a change in therapy would “not lead to meaningful impact” as compared to noting this in only 12% of younger adults (p<.001). CONCLUSION In this real-world, multicenter study, older adults with IBD were more likely to report clinical remission, and were also more likely to achieve endoscopic healing than younger adults. The biggest difference in medication use between the two groups was noted in those with mucosal healing. However, among those not achieving mucosal healing, clinicians were less likely to change therapy for older patients, as they felt it was not likely to have a meaningful impact, even in those with symptoms. Further studies will be needed to better understand these differences in approaches in order to prevent bias in treatment selection. Table 1 Demographics of all patients in the study. Statistically significant differences are noted in bold. * indicates that there were not enough patients to perform statistical analysis. Table 2 Current medication use based on disease activity and patient symptoms. Statistically significant results are noted in bold. * indicates that there were not enough patients to perform statistical analysis.

P561 Reasons for low use of topical 5-ASA formulations in patients treated for ulcerative colitis: comparison of doctors and patients perspectives

P880 The real-world use of five-aminosalicylate (5ASA) treatment for Ulcerative Colitis in Australia and New Zealand: Crohn’s Colitis Cure (CCC) data insight’s program

REAL-WORLD EXPERIENCE AND PERSPECTIVES ON THE TREATMENT OF ULCERATIVE COLITIS: RESULTS FROM A HEALTHCARE PROVIDER SURVEY

P479 Trends in Medication Use and Treatment Patterns in Chinese Patients with Inflammatory Bowel Diseases: A Multicenter Cohort Study from 1999 to 2020

P1004 Proportion of agents for refractory ulcerative colitis and the efficacy of immunomodulator in 5-aminosalicylic acid intolerance

Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL survey

P833 Burden of steroid use in patients with moderate ulcerative colitis in Europe and the United States

P1023 Variability in Mesalazine Management for Ulcerative Proctitis Include Doses, Route of Administration and Use of Fecal Calprotectin: Insights from Clinical Practice Across Spain Beyond Clinical Guidelines

Analysis of the Medication Persistence Rate for and Adherence to Oral 5-Aminosalicylic Acid Preparations in Japanese Patients with Ulcerative Colitis: Study Using a Nationwide Claims Database

Efficacy of Pharmacological Agents for Ulcerative Proctitis: A Systematic Literature Review

P1209 Baseline gut microbiota composition and function reflect response to 5-ASA treatment in Ulcerative Colitis

Motivations behind complementary and alternative medicine use in patients with Crohn's disease and ulcerative colitis

P1000 A meta-analysis and systematic review of 5-aminosalicylates withdrawal in Inflammatory Bowel Disease

P667 Benefit of 5-ASA continuation on UC disease outcomes following initiation of a biologic

P1077 Patients’ and Gastroenterologists’ Preferences on Outcomes and Medication Attributes for Ulcerative colitis

P296 Stopping 5-Aminosalicylic Acid in Patients with Ulcerative Colitis Who Are in Clinical Remission Does Not Increase Risks of Flare

P846 Impact of 5-ASA discontinuation in children with ulcerative colitis under biological therapy

P1054 Clinical outcomes for ulcerative colitis patients stopping 5-aminosalicylates starting biologics and/or immunomodulator therapy: A Systematic review and meta-analysis

Significance of 5-Aminosalicylic Acid Intolerance in the Clinical Management of Ulcerative Colitis

CHRONOLOGICAL AGE INFLUENCES TREATMENT DECISION IN INFLAMMATORY BOWEL DISEASE: AN IBD QORUS COLLABORATIVE STUDY

P931 Burden of disease among Ulcerative Colitis patients with isolated proctitis in the United States and Europe